SEARCH

SEARCH BY CITATION

References

  • 1
    LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:2025.
  • 2
    Kahaleh B. Raynaud's phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 1995; 7:52934.
  • 3
    Famularo G, Procopio A, Giacomelli R et al. Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990; 81:36872.
  • 4
    Needleman BW, Wigley FM, Strair RW et al. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35:6771.
  • 5
    Giacomelli R, Cipriani P, Danese C et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor β1. J Rheumatol 1996; 23:2916.
  • 6
    Famularo G, Giacomelli R, Alesse E et al. Polyclonal B lymphocytes activation in progressive systemic sclerosis. J Clin Lab Immunol 1989; 29:5963.
  • 7
    Yurovsky VV, Sutton PA, Schulze DH et al. Expansion of selected Vδ1 γ/δ T cells in systemic sclerosis patients. J Immunol 1994; 153:88191.
  • 8
    Giacomelli R, Matucci-Cerinic M, Cipriani P et al. Circulating Vδ1 T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthitis Rheum 1998; 41:32734.
  • 9
    Kahaleh MB, Fan PS, Otsuka T. γ/δ receptor bearing T cells in scleroderma: enhanced interaction with vascular endothelial cells in vitro. Clin Immunol 1999; 91:18895.DOI: 10.1006/clim.1999.4694
  • 10
    Kaufmann SHE. γ/δ and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA 1996; 93:22729.DOI: 10.1073/pnas.93.6.2272
  • 11
    Porcelli S, Brenner MB, Band H. Biology of the human γ/δ T cell receptor. Immunol Rev 1991; 120:13783.
  • 12
    Huber SA, Mortensen A, Moulton G. Modulation of cytokine expression by CD4+ T cells during coxsackievirus B3 infections of BALB/c mice initiated by cells expressing the gamma delta+ T cell receptor . J Virol 1996; 70:303947.
  • 13
    Mosmann TR, Schumacher JH, Street NF et al. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev 1991; 123:20929.
  • 14
    Firestein GS, Roeder WD, Laxer JA et al. A new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol 1989; 143:51825.
  • 15
    Druet P, Sheela R, Pelletier L. Th1 and Th2 in autoimmunity. J Exp Immunol 1995; 101 (Suppl. 1):912.
  • 16
    Giacomelli R, Cipriani P, Lattanzio R et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997; 108:426.
  • 17
    Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 1991; 12:1723.
  • 18
    Rosenbloom J, Feldman G, Freundlich B et al. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Arthritis Rheum 1986; 29:8516.
  • 19
    Furst DE, Clements PJ, Graze P et al. A syndrome resembling progressive systemic sclerosis after bone marrow transpantation: a model for scleroderma? Arthritis Rheum 1979; 22:90410.
  • 20
    Rus V, Svetic A, Nguyen P et al. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic graft-vs-host disease. J Immunol 1995; 155:2396406.
  • 21
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:58190.
  • 22
    Brennan P, Silman A, Black C et al. Reliability of skin involvement measures in sceroderma. Br J Rheumatol 1992; 31:45660.
  • 23
    Leivestad T, Gaudernack G, Ugelstad J et al. Positive selection of activated T cells of the T8 (CD8) sub-type by immunomagnetic separation. Tissue Antigens 1986; 28:4652.
  • 24
    Giacomelli R, Passacantando A, Frieri G et al. Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Clin Exp Immunol 1999; 115:727.DOI: 10.1046/j.1365-2249.1999.00741.x
  • 25
    Barnes PF, Abrams JS, Lu S et al. Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect Immun 1993; 61:197202.
  • 26
    Chomorat P, Kjeldsen-Kragh J, Quayle AJ et al. Different cytokine production profiles of γδ T cell clones: relation to inflammatory arthitis. Eur J Immunol 1994; 24:208791.
  • 27
    Duhindam N, Farley AJ, Humphreys S et al. Patterns of lymphokine secretion amongst mouse γδ T cell clones. Eur J Immunol 1997; 27:170412.
  • 28
    Garcìa VE, Sieling PA, Gong J et al. Single-cell cytokine analysis of γδ T cell responses to nonpeptide mycobacterial antigens. J Immunol 1997; 159:132835.
  • 29
    Poccia F, Gougeon ML, Boneville M et al. Innate T-cell immunity to nonpeptidic antigens. Immunol Today 1998; 19:2536.DOI: 10.1016/s0167-5699(98)01266-3
  • 30
    Boullier S, Cochet M, Poccia F et al. CDR3-independent gamma delta V delta 1+ T cell expansion in the peripheral blood of HIV-infected persons. J Immunol 1995; 154:141831.
  • 31
    Vaughan JH, Shaw PX, Nguyen MD et al. Evidence of activation of 2 herpesvirus, Epstein–Barr virus and cytomegalovirus, in systemic sclerosis and normal skin. J Rheumatol 2000; 27:8213.
  • 32
    Alms WJ, Wigley FM, Wise R. Immunological analysis of bronchoalveolar lavage (BAL) cells from scleroderma patients and controls. Arthritis Rheum 1992; 35:s312.
  • 33
    Mavilia C, Scaletti C, Romagnani P et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997; 151:17518.
  • 34
    Kleyn NJ, Rigley KP, Callard RE. IL4 regulates the morphology, cytoskeleton and proliferation of human umbelical vein endothelial cells: relationship between vimentin and IL4. Int Immunol 1992; 5:293302.
  • 35
    Postletwaite AE, Holness MA, Katay H et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992; 90:147985.
  • 36
    White B. immunological aspect of scleroderma. Curr Opin Rheumatol 1994; 6:6125.
  • 37
    Casorati G, Libero G, Lanzavecchia A et al. Molecular analysis of human γδ clones from thymus and peripheral blood. J Exp Med 1989; 170:152135.
  • 38
    Boismenu R & Havran WL. An innate view of γδ T cells. Curr Opin Immunol 1997; 9:5771.
  • 39
    Cifone MG, Giacomelli R, Famularo G et al. Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis. Clin Exp Immunol 1990; 80:3605.
  • 40
    Holcombe RF, Baethge BA, Wolfe RE et al. Natural killer cells and γδ T cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies Ann Rheum Dis 1995; 54:6972.
  • 41
    Kantor TV, Whiteside TL, Friberg D et al. Lymphokine-activated killer cell and natural killer cell activities in patients with systemic sclerosis. Arthitis Rheum 1992; 35:6949.
  • 42
    Artlett CM, Smith B, Jimenez SA. Identification of foetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998; 338:118691.
  • 43
    Mincheva-Nilsson L, Kling M, Hammarstrom S et al. γδ T cells of human early pregnancy decidua. J Immunol 1997; 159:326677.